首页> 外文期刊>Applied immunohistochemistry and molecular morphology: AIMM >Are the Pure In Situ Breast Ductal Carcinomas and Those Associated With Invasive Carcinoma the Same?
【24h】

Are the Pure In Situ Breast Ductal Carcinomas and Those Associated With Invasive Carcinoma the Same?

机译:单纯性原位乳腺导管癌与那些与浸润性癌相关的乳腺癌是否相同?

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

It has been reported that pure ductal carcinoma in situ of the breast has morphologic differences from the in situ component of the invasive ductal carcinoma, as well estrogen and progesterone receptors expression according to their cytokeratin expression. However, there is no data comparing other tumor markers without using the cytokeratin expression. The objective of this study is to compare the expression of estrogen receptor (ER) and progesterone receptor (PR), HER-2eu, p53, and Ki67 between pure ductal in situ carcinoma (pDCIS) and the in situ component of the invasive ductal carcinoma (DCIS + IDC) of the breast, and the in situ component to the invasive component of the same tumor (DCIS + IDC). The immunohistochemistry expression of the tumor markers was performed in 45 cases of pDCIS and DCIS + IDC, yielding a total of 90 cases. Statistical analysis was carried out using Fisher exact test, having a P < 0.05, and Kappa index (k) to assess intratumoral concordance.
机译:据报道,纯乳腺导管癌与浸润性导管癌的原位成分在形态学上有差异,根据它们的细胞角蛋白表达,雌激素和孕激素受体的表达也不同。但是,没有使用细胞角蛋白表达比较其他肿瘤标志物的数据。这项研究的目的是比较纯导管性原位癌(pDCIS)和浸润性原位癌成分之间雌激素受体(ER)和孕激素受体(PR),HER-2 / neu,p53和Ki67的表达乳腺导管癌(DCIS + IDC),并将原位成分引入同一肿瘤的浸润性成分(DCIS + IDC)。在45例pDCIS和DCIS + IDC中进行了肿瘤标志物的免疫组织化学表达,共产生90例。使用Fisher精确检验进行统计学分析,其P <0.05,并且Kappa指数(k)评估肿瘤内一致性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号